Clinical Trials Browser

Phase 1/2 × copanlisib × Clear all

NCT04317105 2026-03-18

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT04345913 2026-03-18

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled 24 charts

Triple Negative Breast Neoplasms

NCT04572763 2026-01-07

Copanlisib Plus Venetoclax in R/R DLBCL

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03711058 2025-09-16

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Phase 1/2 Completed

48 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Spinocerebellar Degenerations

NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Phase 1/2 Withdrawn

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT04253262 2025-05-04

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04939272 2025-05-01

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Mantle-Cell

NCT06218667 2024-10-31

A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

Phase 1/2 Withdrawn

Prostatic Neoplasms

NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Phase 1/2 Terminated

31 enrolled 17 charts

CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT03803761 2023-09-25

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT02342665 2023-01-20

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Phase 1/2 Completed

Lymphoma, Non-Hodgkin

NCT03877055 2022-12-14

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Phase 1/2 Completed

8 enrolled 7 charts

Lymphoma, Mantle-Cell

NCT03052933 2022-06-10

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Phase 1/2 Completed

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT02822482 2021-03-29

COPAN-ORL06

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck